TET2, a tumor suppressor in hematological disorders

Thomas Mercher; Cyril Quivoron; Lucile Couronné; Christian Bastard; William Vainchenker; Olivier A. Bernard

doi:10.1016/j.bbcan.2011.12.002

TET2, a tumor suppressor in hematological disorders

Thomas Mercher, Cyril Quivoron, Lucile Couronné, Christian Bastard, William Vainchenker, Olivier A. Bernard

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

22 Citations (Scopus)

Résumé

The TET family of proteins has been described a few years ago. Only recently, their roles in DNA modification, through the oxidation of methyl-cytosine, and in normal and malignant development, through the description of TET2 as a tumor suppressor have been documented. The conjunction of these findings has prompted large efforts to understand the biology of these novel entities. Here, we summarize the recent results implicating TET2 in hematological malignancies suggesting that further studies are required to fully understand the role of DNA methylation alterations during transformation.

langue originale	Anglais
Pages (de - à)	173-177
Nombre de pages	5
journal	Biochimica et Biophysica Acta - Reviews on Cancer
Volume	1825
Numéro de publication	2
Les DOIs	https://doi.org/10.1016/j.bbcan.2011.12.002
état	Publié - 1 avr. 2012

Accès au document

10.1016/j.bbcan.2011.12.002

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{d5be22165d1e4f4a8968021c5bcd5208,

title = "TET2, a tumor suppressor in hematological disorders",

abstract = "The TET family of proteins has been described a few years ago. Only recently, their roles in DNA modification, through the oxidation of methyl-cytosine, and in normal and malignant development, through the description of TET2 as a tumor suppressor have been documented. The conjunction of these findings has prompted large efforts to understand the biology of these novel entities. Here, we summarize the recent results implicating TET2 in hematological malignancies suggesting that further studies are required to fully understand the role of DNA methylation alterations during transformation.",

keywords = "Epigenetics, Hematology, Mouse models, Oncology, Tumor suppressor",

author = "Thomas Mercher and Cyril Quivoron and Lucile Couronn{\'e} and Christian Bastard and William Vainchenker and Bernard, {Olivier A.}",

note = "Funding Information: The work performed in the authors' laboratories has been funded by INSERM , Institut National du Cancer (INCa) , Ligue Nationale Contre le Cancer (LNCC) , Association de Recherche contre le Cancer (ARC) and Fondation Gustave Roussy .",

year = "2012",

month = apr,

day = "1",

doi = "10.1016/j.bbcan.2011.12.002",

language = "English",

volume = "1825",

pages = "173--177",

journal = "Biochimica et Biophysica Acta - Reviews on Cancer",

issn = "0304-419X",

number = "2",

}

TY - JOUR

T1 - TET2, a tumor suppressor in hematological disorders

AU - Mercher, Thomas

AU - Quivoron, Cyril

AU - Couronné, Lucile

AU - Bastard, Christian

AU - Vainchenker, William

AU - Bernard, Olivier A.

N1 - Funding Information: The work performed in the authors' laboratories has been funded by INSERM , Institut National du Cancer (INCa) , Ligue Nationale Contre le Cancer (LNCC) , Association de Recherche contre le Cancer (ARC) and Fondation Gustave Roussy .

PY - 2012/4/1

Y1 - 2012/4/1

N2 - The TET family of proteins has been described a few years ago. Only recently, their roles in DNA modification, through the oxidation of methyl-cytosine, and in normal and malignant development, through the description of TET2 as a tumor suppressor have been documented. The conjunction of these findings has prompted large efforts to understand the biology of these novel entities. Here, we summarize the recent results implicating TET2 in hematological malignancies suggesting that further studies are required to fully understand the role of DNA methylation alterations during transformation.

AB - The TET family of proteins has been described a few years ago. Only recently, their roles in DNA modification, through the oxidation of methyl-cytosine, and in normal and malignant development, through the description of TET2 as a tumor suppressor have been documented. The conjunction of these findings has prompted large efforts to understand the biology of these novel entities. Here, we summarize the recent results implicating TET2 in hematological malignancies suggesting that further studies are required to fully understand the role of DNA methylation alterations during transformation.

KW - Epigenetics

KW - Hematology

KW - Mouse models

KW - Oncology

KW - Tumor suppressor

UR - http://www.scopus.com/inward/record.url?scp=84856069777&partnerID=8YFLogxK

U2 - 10.1016/j.bbcan.2011.12.002

DO - 10.1016/j.bbcan.2011.12.002

M3 - Review article

C2 - 22240200

AN - SCOPUS:84856069777

SN - 0304-419X

VL - 1825

SP - 173

EP - 177

JO - Biochimica et Biophysica Acta - Reviews on Cancer

JF - Biochimica et Biophysica Acta - Reviews on Cancer

IS - 2

ER -